23444215	207	Catalanotti F	Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.	Clinical cancer research 	2013	36
19671850	238	Rodig SJ	Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.	Clinical cancer research 	2009	141
21336183	238	Camidge DR	Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.	Journal of thoracic oncology 	2011	61
21642865	238	Lee JO	Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.	Journal of thoracic oncology 	2011	39
21933749	238	Shaw AT	Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.	The Lancet. Oncology	2011	199
22071784	238	McLeer-Florin A	Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study.	Journal of thoracic oncology 	2012	40
22129856	238	Paik JH	Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma.	Lung cancer	2012	34
23344087	238	Kim S	Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.	Journal of thoracic oncology 	2013	38
21285991	673	Yokota T	BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer.	British journal of cancer	2011	79
27080216	673	Planchard D	Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.	The Lancet. Oncology	2016	18
19609742	1019	Rao SK	A survey of glioblastoma genomic amplifications and deletions.	Journal of neuro-oncology	2010	46
25609060	1019	Di Stefano AL	Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.	Clinical cancer research 	2015	19
16854453	1026	McCubrey JA	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.	Advances in enzyme regulation	2006	155
22580610	1026	Yin D	miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.	Oncogene	2013	28
15466178	1029	Ohgaki H	Genetic pathways to glioblastoma: a population-based study.	Cancer research	2004	283
15977639	1029	Ohgaki H	Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.	Journal of neuropathology and experimental neurology	2005	238
17456751	1029	Ohgaki H	Genetic pathways to primary and secondary glioblastoma.	The American journal of pathology	2007	299
18474878	1029	Kumar B	EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer.	Journal of clinical oncology 	2008	169
22975375	1029	Navas C	EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.	Cancer cell	2012	91
23412337	1029	Sottoriva A	Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.	Proceedings of the National Academy of Sciences of the United States of America	2013	267
23663786	1029	Yang L	Diverse mechanisms of somatic structural variations in human cancer genomes.	Cell	2013	74
23887298	1029	Ross JS	Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.	Modern pathology 	2014	36
23907151	1029	Kanagal-Shamanna R	Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.	Modern pathology 	2014	33
24425785	1029	Li H	Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.	Molecular cancer research 	2014	21
25117714	1029	Ozawa T	Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.	Cancer cell	2014	54
25536104	1029	Churi CR	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.	PloS one	2014	40
25589618	1029	Li YY	Genomic analysis of metastatic cutaneous squamous cell carcinoma.	Clinical cancer research 	2015	17
26873401	1029	Sawada G	Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.	Gastroenterology	2016	17
24548766	1048	Yang CY	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.	European journal of cancer	2014	59
22586683	1399	Cheung HW	Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.	Cancer discovery	2011	45
16046538	1432	Carter TA	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.	Proceedings of the National Academy of Sciences of the United States of America	2005	116
21306997	1432	Sunaga N	Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.	Molecular cancer therapeutics	2011	54
25877892	1496	McGranahan N	Clonal status of actionable driver events and the timing of mutational processes in cancer evolution.	Science translational medicine	2015	55
19078924	1499	Bansal N	The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies.	Cancer control 	2009	64
22071650	1499	Sequist LV	Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.	Annals of oncology 	2011	92
22538770	1499	Santarpia L	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.	Breast cancer research and treatment	2012	35
22975805	1499	Seo JS	The transcriptional landscape and mutational profile of lung adenocarcinoma.	Genome research	2012	139
23325582	1499	Peeters M	Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer.	Clinical cancer research 	2013	56
18291115	1950	Lafky JM	Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.	Biochimica et biophysica acta	2008	73
18379349	1950	Beau-Faller M	MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.	Journal of thoracic oncology 	2008	60
1557402	1956	Wong AJ	Structural alterations of the epidermal growth factor receptor gene in human gliomas.	Proceedings of the National Academy of Sciences of the United States of America	1992	188
3477813	1956	Wong AJ	Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.	Proceedings of the National Academy of Sciences of the United States of America	1987	173
9006938	1956	Huang HS	The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.	The Journal of biological chemistry	1997	162
10728703	1956	Frederick L	Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.	Cancer research	2000	153
11504770	1956	Smith JS	PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.	Journal of the National Cancer Institute	2001	100
14583498	1956	Shinojima N	Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.	Cancer research	2003	158
15057284	1956	Qian X	E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases.	The EMBO journal	2004	106
15118073	1956	Lynch TJ	Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2004	2248
15118125	1956	Paez JG	EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.	Science	2004	1967
15329413	1956	Pao W	EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2004	1001
15604253	1956	Kosaka T	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.	Cancer research	2004	233
15623594	1956	Huang SF	High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.	Clinical cancer research 	2004	78
15665299	1956	Amann J	Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.	Cancer research	2005	99
15681531	1956	Marchetti A	EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.	Journal of clinical oncology 	2005	149
15709185	1956	Tokumo M	The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.	Clinical cancer research 	2005	94
15710947	1956	Han SW	Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.	Journal of clinical oncology 	2005	135
15728811	1956	Kobayashi S	EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.	The New England journal of medicine	2005	834
15735034	1956	Stabile LP	Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.	Cancer research	2005	82
15737014	1956	Pao W	Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.	PLoS medicine	2005	874
15738541	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.	Journal of clinical oncology 	2005	175
15741570	1956	Shigematsu H	Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.	Journal of the National Cancer Institute	2005	439
15753357	1956	Shigematsu H	Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.	Cancer research	2005	142
15767641	1956	Pao W	Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.	Journal of clinical oncology 	2005	94
15831234	1956	Giannini C	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.	Neuro-oncology	2005	158
15863375	1956	Moroni M	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.	The Lancet. Oncology	2005	197
15870435	1956	Cappuzzo F	Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.	Journal of the National Cancer Institute	2005	311
15886310	1956	Jänne PA	Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.	Journal of clinical oncology 	2005	82
15920544	1956	Bhargava R	EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.	Modern pathology 	2005	76
15956649	1956	Haas-Kogan DA	Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.	Journal of the National Cancer Institute	2005	132
15994928	1956	Zhao X	Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.	Cancer research	2005	120
15998907	1956	Takano T	Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.	Journal of clinical oncology 	2005	139
16014883	1956	Tsao MS	Erlotinib in lung cancer - molecular and clinical predictors of outcome.	The New England journal of medicine	2005	312
16033833	1956	Lakhani SR	Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.	Clinical cancer research 	2005	149
16049312	1956	Pan Q	Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.	The Journal of molecular diagnostics 	2005	74
16061871	1956	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	66
16105816	1956	Nagai Y	Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.	Cancer research	2005	91
16161046	1956	Hanawa M	EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus.	International journal of cancer	2006	67
16204011	1956	Bell DW	Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.	Journal of clinical oncology 	2005	119
16230383	1956	Baird K	Gene expression profiling of human sarcomas: insights into sarcoma biology.	Cancer research	2005	85
16231326	1956	Shigematsu H	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.	International journal of cancer	2006	139
16282176	1956	Mellinghoff IK	Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.	The New England journal of medicine	2005	399
16322287	1956	Haura EB	Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.	Clinical cancer research 	2005	70
16361555	1956	Yauch RL	Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.	Clinical cancer research 	2005	161
16377102	1956	Normanno N	Epidermal growth factor receptor (EGFR) signaling in cancer.	Gene	2006	351
16467097	1956	Riely GJ	Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2006	174
16533793	1956	Tam IY	Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.	Clinical cancer research 	2006	112
16540667	1956	Alvarez JV	Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.	Cancer research	2006	61
16549822	1956	Takeuchi T	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.	Journal of clinical oncology 	2006	64
16730237	1956	Ji H	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.	Cancer cell	2006	125
16740687	1956	Song L	Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.	Cancer research	2006	73
16785471	1956	Inoue A	Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.	Journal of clinical oncology 	2006	116
16818686	1956	Jackman DM	Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.	Clinical cancer research 	2006	120
16818687	1956	Kimura H	Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.	Clinical cancer research 	2006	67
16837691	1956	Zakowski MF	EGFR mutations in small-cell lung cancers in patients who have never smoked.	The New England journal of medicine	2006	65
16890793	1956	Mendelsohn J	Epidermal growth factor receptor targeting in cancer.	Seminars in oncology	2006	150
17020982	1956	Kosaka T	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.	Clinical cancer research 	2006	131
17047648	1956	Asahina H	A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.	British journal of cancer	2006	67
17075123	1956	Hirsch FR	Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2006	145
17085664	1956	Balak MN	Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.	Clinical cancer research 	2006	196
17126425	1956	McCubrey JA	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.	Biochimica et biophysica acta	2007	423
17189395	1956	Ono M	Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.	Clinical cancer research 	2006	80
17218988	1956	Kenny PA	Targeting TACE-dependent EGFR ligand shedding in breast cancer.	The Journal of clinical investigation	2007	72
17228019	1956	Jackman DM	Phase II clinical trial of chemotherapy-naive patients &amp;gt; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2007	82
17283074	1956	Hsu SC	Characterization of a novel tripartite nuclear localization sequence in the EGFR family.	The Journal of biological chemistry	2007	83
17290066	1956	Subramanian J	Lung cancer in never smokers: a review.	Journal of clinical oncology 	2007	142
17290067	1956	Sequist LV	Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.	Journal of clinical oncology 	2007	144
17308052	1956	Buck E	Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.	Molecular cancer therapeutics	2007	70
17317677	1956	Hirsch FR	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.	Annals of oncology 	2007	69
17332364	1956	Mulloy R	Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.	Cancer research	2007	62
17404082	1956	Shaffer DR	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.	Clinical cancer research 	2007	98
17473659	1956	Wu YL	Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.	Journal of thoracic oncology 	2007	58
17504988	1956	Massarelli E	KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Clinical cancer research 	2007	154
17538160	1956	Temam S	Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.	Journal of clinical oncology 	2007	89
17664471	1956	Khambata-Ford S	Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.	Journal of clinical oncology 	2007	291
17785346	1956	Krex D	Long-term survival with glioblastoma multiforme.	Brain 	2007	171
17888036	1956	Mitsudomi T	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.	Cancer science	2007	121
17974918	1956	Okawa T	The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation.	Genes and development	2007	65
18060032	1956	Gao SP	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.	The Journal of clinical investigation	2007	193
18093943	1956	Bean J	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.	Proceedings of the National Academy of Sciences of the United States of America	2007	447
18281673	1956	Eberhard DA	Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.	Journal of clinical oncology 	2008	68
18283321	1956	Tamura K	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).	British journal of cancer	2008	54
18303429	1956	Marks JL	Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.	Journal of thoracic oncology 	2008	71
18304967	1956	Weiss GJ	EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.	Annals of oncology 	2008	74
18325048	1956	Taniguchi K	Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.	Cancer science	2008	61
18339877	1956	Jhawer M	PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.	Cancer research	2008	130
18349398	1956	Miller VA	Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.	Journal of clinical oncology 	2008	66
18375904	1956	Kumar A	Structure and clinical relevance of the epidermal growth factor receptor in human cancer.	Journal of clinical oncology 	2008	58
18391747	1956	Motoi N	Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.	The American journal of surgical pathology	2008	77
18408761	1956	Li D	BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.	Oncogene	2008	268
18413800	1956	Godin-Heymann N	The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.	Molecular cancer therapeutics	2008	58
18437168	1956	Ladanyi M	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.	Modern pathology 	2008	71
18458038	1956	Sequist LV	First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.	Journal of clinical oncology 	2008	233
18483355	1956	Engelman JA	Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2008	188
18509184	1956	Yang CH	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.	Journal of clinical oncology 	2008	56
18596266	1956	Maheswaran S	Detection of mutations in EGFR in circulating lung-cancer cells.	The New England journal of medicine	2008	403
18626007	1956	Zhu CQ	Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.	Journal of clinical oncology 	2008	161
18676761	1956	Wu JY	Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.	Clinical cancer research 	2008	71
18794099	1956	Personeni N	Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.	Clinical cancer research 	2008	51
18802721	1956	van Krieken JH	KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.	Virchows Archiv 	2008	73
18927285	1956	Fichtner I	Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.	Clinical cancer research 	2008	85
18948947	1956	Ding L	Somatic mutations affect key pathways in lung adenocarcinoma.	Nature	2008	866
18981003	1956	Costa DB	Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.	Clinical cancer research 	2008	54
19010870	1956	Bean J	Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.	Clinical cancer research 	2008	78
19010912	1956	Pratilas CA	Genetic predictors of MEK dependence in non-small cell lung cancer.	Cancer research	2008	83
19010923	1956	Yano S	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.	Cancer research	2008	170
19088172	1956	Gow CH	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.	Annals of oncology 	2009	47
19096300	1956	Onozato R	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.	Journal of thoracic oncology 	2009	61
19170230	1956	Wong DW	The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.	Cancer	2009	157
19188670	1956	Allegra CJ	American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.	Journal of clinical oncology 	2009	311
19224850	1956	Inoue A	First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.	Journal of clinical oncology 	2009	84
19234440	1956	Inamura K	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.	Modern pathology 	2009	103
19238632	1956	Tang Z	Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.	British journal of cancer	2008	57
19252415	1956	Golding SE	Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.	Cancer biology and therapy	2009	49
19255323	1956	Cappuzzo F	Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.	Journal of clinical oncology 	2009	114
19276259	1956	Yung TK	Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.	Clinical cancer research 	2009	99
19351754	1956	Kuang Y	Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.	Clinical cancer research 	2009	65
19366827	1956	Yu J	Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.	Clinical cancer research 	2009	54
19412429	1956	Pillay V	The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.	Neoplasia	2009	48
19414683	1956	Bai H	Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	84
19447865	1956	Naumov GN	Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.	Clinical cancer research 	2009	55
19483740	1956	Linardou H	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.	Nature reviews. Clinical oncology	2009	57
19536109	1956	Walther A	Genetic prognostic and predictive markers in colorectal cancer.	Nature reviews. Cancer	2009	171
19584155	1956	Schmid K	EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.	Clinical cancer research 	2009	66
19632948	1956	Nguyen KS	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.	Clinical lung cancer	2009	109
19636327	1956	Normanno N	Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.	Nature reviews. Clinical oncology	2009	107
19667264	1956	Shaw AT	Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.	Journal of clinical oncology 	2009	384
19671843	1956	Jackman DM	Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.	Clinical cancer research 	2009	111
19680293	1956	Gazdar AF	Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.	Oncogene	2009	164
19690143	1956	Lu KV	Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.	Cancer research	2009	55
19692680	1956	Mok TS	Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.	The New England journal of medicine	2009	1546
19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
19723643	1956	Krishnaswamy S	Ethnic differences and functional analysis of MET mutations in lung cancer.	Clinical cancer research 	2009	56
19738166	1956	Siena S	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.	Journal of the National Cancer Institute	2009	144
19806185	1956	Sartore-Bianchi A	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.	PloS one	2009	85
19826477	1956	Soh J	Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.	PloS one	2009	66
19884556	1956	Laurent-Puig P	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.	Journal of clinical oncology 	2009	189
19917871	1956	Azzoli CG	American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.	Journal of clinical oncology 	2009	139
19942479	1956	Folprecht G	Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.	The Lancet. Oncology	2010	132
19949011	1956	Jackman D	Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.	Journal of clinical oncology 	2010	157
20022809	1956	Mitsudomi T	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.	The Lancet. Oncology	2010	783
20028749	1956	Dahabreh IJ	Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.	Clinical cancer research 	2010	44
20038723	1956	Douillard JY	Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.	Journal of clinical oncology 	2010	141
20100958	1956	Khambata-Ford S	Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	63
20100961	1956	Bardelli A	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.	Journal of clinical oncology 	2010	160
20103678	1956	Baldus SE	Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.	Clinical cancer research 	2010	109
20108024	1956	Suda K	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.	Cancer metastasis reviews	2010	44
20118985	1956	Ercan D	Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.	Oncogene	2010	63
20124471	1956	McDermott U	Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.	Cancer research	2010	51
20129249	1956	Turke AB	Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.	Cancer cell	2010	280
20146086	1956	Clarke JL	High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer.	Journal of neuro-oncology	2010	50
20183914	1956	Takahashi T	Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.	Annals of surgical oncology	2010	80
20351699	1956	Harris TJ	The molecular pathology of cancer.	Nature reviews. Clinical oncology	2010	57
20399983	1956	Tol J	Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.	Clinical therapeutics	2010	50
20479403	1956	Sequist LV	Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	96
20493771	1956	Cappuzzo F	Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.	The Lancet. Oncology	2010	278
20530271	1956	Lubner SJ	Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.	Journal of clinical oncology 	2010	55
20551945	1956	Janku F	Targeted therapy in non-small-cell lung cancer--is it becoming a reality?	Nature reviews. Clinical oncology	2010	61
20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	981
20595147	1956	Porta R	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.	The European respiratory journal	2011	60
20624322	1956	Zhang X	Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.	Molecular cancer	2010	79
20627894	1956	Eichler AF	EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.	Neuro-oncology	2010	48
20679611	1956	Yap TA	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.	Journal of clinical oncology 	2010	77
20824720	1956	da Cunha Santos G	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.	Cancer	2010	42
20838621	1956	Punnoose EA	Molecular biomarker analyses using circulating tumor cells.	PloS one	2010	78
20855820	1956	Johnson FM	Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.	Journal of clinical oncology 	2010	53
20855837	1956	Sun Y	Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.	Journal of clinical oncology 	2010	93
20864632	1956	Attolini CS	A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.	Proceedings of the National Academy of Sciences of the United States of America	2010	47
20871269	1956	Pirker R	Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.	Journal of thoracic oncology 	2010	57
20887192	1956	da Cunha Santos G	EGFR mutations and lung cancer.	Annual review of pathology	2011	65
20921461	1956	Roberts PJ	Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?	Journal of clinical oncology 	2010	77
20921462	1956	Peeters M	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2010	181
20921465	1956	Douillard JY	Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.	Journal of clinical oncology 	2010	343
20940188	1956	Sequist LV	Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer.	Journal of clinical oncology 	2010	100
20966921	1956	Pao W	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.	Nature reviews. Cancer	2010	239
21030498	1956	Heon S	Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.	Clinical cancer research 	2010	44
21062932	1956	Camidge DR	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.	Clinical cancer research 	2010	75
21062933	1956	Suda K	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.	Clinical cancer research 	2010	47
21081655	1956	John T	The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.	Clinical cancer research 	2011	38
21135146	1956	Oxnard GR	Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.	Clinical cancer research 	2011	102
21163703	1956	De Roock W	KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.	The Lancet. Oncology	2011	127
21168239	1956	Chung JH	Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.	Lung cancer	2011	39
21200037	1956	Dahabreh IJ	Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.	Annals of internal medicine	2011	47
21220471	1956	Jänne PA	Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.	Clinical cancer research 	2011	39
21220474	1956	Donev IS	Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.	Clinical cancer research 	2011	37
21233402	1956	Rosell R	Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.	Clinical cancer research 	2011	78
21248300	1956	Arcila ME	Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.	Clinical cancer research 	2011	120
21248303	1956	Janjigian YY	Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.	Clinical cancer research 	2011	46
21258250	1956	Ludovini V	Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.	Journal of thoracic oncology 	2011	44
21258415	1956	Normant E	The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.	Oncogene	2011	46
21266349	1956	Liccardi G	EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment.	Cancer research	2011	65
21266357	1956	Qi J	Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.	Cancer research	2011	49
21277552	1956	Pao W	New driver mutations in non-small-cell lung cancer.	The Lancet. Oncology	2011	244
21289483	1956	Cho WC	MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1.	RNA biology	2011	53
21303969	1956	Ramalingam SS	Lung cancer: New biological insights and recent therapeutic advances.	CA	2011	87
21408138	1956	van Eijk R	Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR.	PloS one	2011	43
21422426	1956	Zander T	Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using (18)Ffluorodeoxyglucose and (18)Ffluorothymidine positron emission tomography.	Journal of clinical oncology 	2011	37
21430269	1956	Sequist LV	Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.	Science translational medicine	2011	622
21430781	1956	Bivona TG	FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.	Nature	2011	99
21482987	1956	D'Angelo SP	Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.	Journal of clinical oncology 	2011	59
21482992	1956	Keedy VL	American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.	Journal of clinical oncology 	2011	117
21483012	1956	Paik PK	Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.	Journal of clinical oncology 	2011	116
21531810	1956	Wu JY	Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.	Clinical cancer research 	2011	86
21597390	1956	Suda K	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.	Journal of thoracic oncology 	2011	69
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	201
21646616	1956	Price TJ	Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.	Journal of clinical oncology 	2011	58
21670455	1956	Fukuoka M	Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).	Journal of clinical oncology 	2011	295
21687663	1956	Li N	Inhibition of cell proliferation by an anti-EGFR aptamer.	PloS one	2011	41
21720997	1956	Kim HR	Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.	Cancer	2012	33
21730270	1956	Yatabe Y	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.	Journal of clinical oncology 	2011	46
21734175	1956	Chmielecki J	Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.	Science translational medicine	2011	156
21764376	1956	Yasuda H	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.	The Lancet. Oncology	2012	80
21768463	1956	Sequist LV	Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.	Journal of clinical oncology 	2011	120
21775534	1956	Oxnard GR	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clinical cancer research 	2011	84
21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
21788562	1956	Zhou Q	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	61
21791641	1956	Sasaki T	A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.	Cancer research	2011	157
21856766	1956	Chaft JE	Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.	Clinical cancer research 	2011	90
21865399	1956	Grommes C	"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.	Neuro-oncology	2011	57
21900837	1956	Goto K	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	Journal of thoracic oncology 	2012	51
21969500	1956	Brugger W	Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.	Journal of clinical oncology 	2011	68
21976538	1956	Taniguchi K	Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.	Clinical cancer research 	2011	75
22025148	1956	Lai A	Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.	Journal of clinical oncology 	2011	91
22025157	1956	Ramalingam SS	Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.	Journal of clinical oncology 	2011	59
22042947	1956	Lennerz JK	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.	Journal of clinical oncology 	2011	116
22052230	1956	Yano S	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.	Journal of thoracic oncology 	2011	47
22054879	1956	Travis WD	Pathology of lung cancer.	Clinics in chest medicine	2011	60
22119437	1956	Soria JC	EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.	Cancer treatment reviews	2012	35
22135231	1956	Chaft JE	Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.	Molecular cancer therapeutics	2012	55
22137795	1956	Snuderl M	Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.	Cancer cell	2011	184
22139077	1956	Bonavia R	EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway.	Oncogene	2012	52
22140546	1956	Li C	Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.	PloS one	2011	54
22178589	1956	Andersen JB	Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.	Gastroenterology	2012	76
22186794	1956	Parato KA	The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.	Molecular therapy 	2012	48
22194472	1956	Ju YS	A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.	Genome research	2012	122
22209049	1956	O'Flaherty JD	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer.	Lung cancer	2012	44
22215752	1956	Su KY	Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	111
22228640	1956	Rekhtman N	Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.	Clinical cancer research 	2012	73
22228822	1956	Kim Y	The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor.	Molecular cancer therapeutics	2012	34
22235099	1956	Doebele RC	Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.	Clinical cancer research 	2012	213
22237264	1956	Sun PL	High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.	Journal of thoracic oncology 	2012	34
22270724	1956	Montagut C	Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.	Nature medicine	2012	100
22282022	1956	Doebele RC	Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.	Cancer	2012	48
22282308	1956	Cheng L	Molecular pathology of lung cancer: key to personalized medicine.	Modern pathology 	2012	41
22285168	1956	Rosell R	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.	The Lancet. Oncology	2012	877
22315472	1956	Deng N	A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.	Gut	2012	127
22317764	1956	Zhang Y	Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.	Clinical cancer research 	2012	46
22407829	1956	Perez-Moreno P	Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities.	Clinical cancer research 	2012	48
22440336	1956	Scagliotti GV	Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.	Clinical lung cancer	2012	44
22448344	1956	Corcoran RB	EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.	Cancer discovery	2012	180
22452803	1956	Fokas E	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.	Radiation oncology	2012	30
22452895	1956	Yang JC	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.	The Lancet. Oncology	2012	76
22464348	1956	Couraud S	Lung cancer in never smokers--a review.	European journal of cancer	2012	51
22492982	1956	Punnoose EA	Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.	Clinical cancer research 	2012	76
22505743	1956	Navani N	Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: a multicenter study of 774 patients.	American journal of respiratory and critical care medicine	2012	53
22547605	1956	Jänne PA	Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.	Journal of clinical oncology 	2012	75
22552284	1956	Turke AB	MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors.	Cancer research	2012	72
22588883	1956	Vivanco I	Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.	Cancer discovery	2012	73
22590557	1956	Wilkerson MD	Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation.	PloS one	2012	45
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	210
22673630	1956	Chen ZY	EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.	The oncologist	2012	36
22677429	1956	Park SJ	Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.	Lung cancer	2012	50
22722830	1956	Misale S	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.	Nature	2012	335
22722843	1956	Diaz LA Jr	The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.	Nature	2012	380
22751098	1956	Zhang Z	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.	Nature genetics	2012	265
22768234	1956	An SJ	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.	PloS one	2012	50
22773810	1956	Ohashi K	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.	Proceedings of the National Academy of Sciences of the United States of America	2012	122
22778317	1956	Gridelli C	First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.	Journal of clinical oncology 	2012	54
22797485	1956	Zhao X	Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.	Respiration; international review of thoracic diseases	2013	30
22810899	1956	Johnson ML	Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.	Cancer	2013	32
22826274	1956	Bai H	Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.	Journal of clinical oncology 	2012	60
22891331	1956	Fenton TR	Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.	Proceedings of the National Academy of Sciences of the United States of America	2012	32
22956860	1956	Creighton CJ	The molecular profile of luminal B breast cancer.	Biologics 	2012	45
22961667	1956	Ercan D	Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.	Cancer discovery	2012	77
22964225	1956	Johnson H	Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.	Molecular and cellular proteomics 	2012	30
22967997	1956	Inoue A	Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).	Annals of oncology 	2013	73
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2336
23014527	1956	Dogan S	Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.	Clinical cancer research 	2012	74
23021375	1956	Berg M	EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.	Discovery medicine	2012	32
23079155	1956	Yang JJ	Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.	Lung cancer	2013	34
23091115	1956	Byers LA	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.	Clinical cancer research 	2013	177
23103856	1956	Young A	Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.	Cancer discovery	2013	48
23123196	1956	Yang W	EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis.	Molecular cell	2012	56
23129122	1956	Wu YL	Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).	Annals of oncology 	2013	37
23136247	1956	Gasch C	Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer.	Clinical chemistry	2013	55
23154552	1956	Weickhardt AJ	Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.	Journal of thoracic oncology 	2012	81
23154553	1956	D'Angelo SP	Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.	Journal of thoracic oncology 	2012	36
23172555	1956	Ellison G	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.	Journal of clinical pathology	2013	49
23233388	1956	Mostert B	KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue.	International journal of cancer	2013	30
23242438	1956	Yoshizawa A	Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.	Journal of thoracic oncology 	2013	67
23242808	1956	Girotti MR	Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.	Cancer discovery	2013	100
23265711	1956	Licitra L	Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies.	European journal of cancer	2013	27
23332287	1956	Gadgeel SM	Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.	Clinical lung cancer	2013	29
23341526	1956	Welsh JW	Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.	Journal of clinical oncology 	2013	71
23341890	1956	Li Y	Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.	PloS one	2013	41
23344264	1956	Yeh P	DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.	Clinical cancer research 	2013	35
23362162	1956	Tuononen K	Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.	Genes, chromosomes and cancer	2013	34
23370315	1956	Hirsch FR	Epidermal growth factor receptor inhibition in lung cancer: status 2012.	Journal of thoracic oncology 	2013	26
23391413	1956	Voss JS	Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.	Human pathology	2013	38
23401440	1956	Roberts PJ	KRAS mutation: should we test for it, and does it matter?	Journal of clinical oncology 	2013	55
23401448	1956	Mok T	Treating patients with EGFR-sensitizing mutations: first line or second line--is there a difference?	Journal of clinical oncology 	2013	27
23401451	1956	Ohashi K	Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.	Journal of clinical oncology 	2013	103
23401452	1956	Laurie SA	Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.	Journal of clinical oncology 	2013	29
23404247	1956	Valtorta E	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.	International journal of cancer	2013	34
23407558	1956	Yu HA	Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors.	Journal of thoracic oncology 	2013	49
23470965	1956	Yu HA	Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.	Clinical cancer research 	2013	256
23486266	1956	Russell PA	Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.	Journal of thoracic oncology 	2013	29
23552377	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	Journal of thoracic oncology 	2013	124
23553849	1956	Socinski MA	A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.	Clinical cancer research 	2013	70
23562183	1956	Lindeman NI	Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.	The Journal of molecular diagnostics 	2013	61
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	261
23589544	1956	Buettner R	Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment.	Journal of clinical oncology 	2013	33
23594426	1956	Lee CK	Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.	Journal of the National Cancer Institute	2013	99
23676460	1956	Banck MS	The genomic landscape of small intestine neuroendocrine tumors.	The Journal of clinical investigation	2013	36
23707073	1956	Babic I	EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer.	Cell metabolism	2013	30
23723294	1956	Dearden S	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).	Annals of oncology 	2013	58
23729361	1956	Gainor JF	ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.	Clinical cancer research 	2013	85
23768755	1956	Roengvoraphoj M	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.	Cancer treatment reviews	2013	25
23777544	1956	Gan HK	The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered.	The FEBS journal	2013	46
23814043	1956	Gainor JF	Novel targets in non-small cell lung cancer: ROS1 and RET fusions.	The oncologist	2013	35
23816960	1956	Sequist LV	Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	383
23816963	1956	Katakami N	LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.	Journal of clinical oncology 	2013	64
23816967	1956	Yang JC	Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.	Journal of clinical oncology 	2013	49
23829935	1956	Remon J	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins.	Cancer treatment reviews	2014	22
23833300	1956	Cardarella S	Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.	Clinical cancer research 	2013	36
23852704	1956	Duffy MJ	Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update.	International journal of cancer	2014	26
23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
23888061	1956	Liu X	The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies.	Journal of clinical pathology	2013	29
23891509	1956	Tsuta K	The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.	Lung cancer	2013	35
23894143	1956	Li R	Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer.	Molecular cancer therapeutics	2013	32
23931927	1956	Gridelli C	ALK inhibitors in the treatment of advanced NSCLC.	Cancer treatment reviews	2014	34
23948351	1956	Shi Y	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.	The Lancet. Oncology	2013	73
23953842	1956	Yewale C	Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.	Biomaterials	2013	44
23972815	1956	Rosell R	Genetics and biomarkers in personalisation of lung cancer treatment.	Lancet	2013	60
23980091	1956	Goss GD	Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.	Journal of clinical oncology 	2013	40
24021541	1956	Iuchi T	Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.	Lung cancer	2013	31
24034250	1956	Wei Y	EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance.	Cell	2013	104
24065147	1956	Niederst MJ	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Science signaling	2013	53
24065731	1956	Walter AO	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.	Cancer discovery	2013	123
24072220	1956	Goldberg SB	Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.	The oncologist	2013	37
24098024	1956	Pichler M	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor.	Journal of clinical pathology	2014	26
24105277	1956	Hata A	Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.	Cancer	2013	38
24135280	1956	Fan QW	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma.	Cancer cell	2013	50
24141978	1956	Zhang L	A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.	Scientific reports	2013	28
24199682	1956	Yamaguchi N	Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.	Lung cancer	2014	23
24202392	1956	Chong CR	The quest to overcome resistance to EGFR-targeted therapies in cancer.	Nature medicine	2013	169
24236184	1956	Scarpa A	Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.	PloS one	2013	28
24263064	1956	Douillard JY	First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.	British journal of cancer	2014	35
24269963	1956	Roskoski R Jr	The ErbB/HER family of protein-tyrosine kinases and cancer.	Pharmacological research	2014	122
24310612	1956	Nathanson DA	Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA.	Science	2014	70
24353160	1956	Yasuda H	Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.	Science translational medicine	2013	45
24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
24378644	1956	Siegelin MD	Epidermal growth factor receptor mutations in lung adenocarcinoma.	Laboratory investigation; a journal of technical methods and pathology	2014	40
24384534	1956	Maroun CR	The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.	Pharmacology and therapeutics	2014	31
24406864	1956	Park HS	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.	Modern pathology 	2014	33
24419411	1956	Shi Y	A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).	Journal of thoracic oncology 	2014	114
24429876	1956	Oxnard GR	Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.	Clinical cancer research 	2014	111
24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
24443522	1956	Yang JJ	Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.	Clinical cancer research 	2014	29
24458568	1956	Suda K	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.	International journal of cancer	2014	22
24478319	1956	Yu HA	Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.	Annals of oncology 	2014	24
24501009	1956	Reckamp KL	A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.	Cancer	2014	24
24513263	1956	Vanderlaan PA	Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer.	Lung cancer	2014	20
24533047	1956	Liang W	Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.	PloS one	2014	21
24550739	1956	Borad MJ	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS genetics	2014	55
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
24666267	1956	Therkildsen C	The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.	Acta oncologica	2014	56
24670642	1956	Sun C	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.	Nature	2014	140
24685132	1956	Sun C	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.	Cell reports	2014	43
24687921	1956	Koeppen H	Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.	Clinical cancer research 	2014	26
24715074	1956	Lee JK	Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.	JAMA	2014	27
24743704	1956	Li S	Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.	British journal of cancer	2014	25
24773774	1956	Weber B	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays.	BMC cancer	2014	25
24841974	1956	Kawaguchi T	Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).	Journal of clinical oncology 	2014	53
24846037	1956	Kris MG	Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.	JAMA	2014	183
24857124	1956	Gerber DE	Management and future directions in non-small cell lung cancer with known activating mutations.	American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting	2014	23
24868098	1956	Khozin S	U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.	The oncologist	2014	20
24893891	1956	Cross DA	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.	Cancer discovery	2014	172
24919575	1956	Yoshida T	Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.	Clinical cancer research 	2014	21
24939055	1956	Qu Y	Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.	Journal of experimental and clinical cancer research 	2014	22
25009014	1956	Azuma K	Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.	Annals of oncology 	2014	66
25013125	1956	Couraud S	Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.	Clinical cancer research 	2014	40
25031274	1956	Lee SM	Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.	Journal of the National Cancer Institute	2014	22
25057166	1956	Missiaglia E	Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.	Annals of oncology 	2014	38
25074459	1956	Janjigian YY	Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.	Cancer discovery	2014	71
25079552	1956	Cancer Genome Atlas Research Network.	Comprehensive molecular profiling of lung adenocarcinoma.	Nature	2014	570
25080476	1956	Müller C	Hematogenous dissemination of glioblastoma multiforme.	Science translational medicine	2014	27
25103305	1956	Sorensen BS	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.	Cancer	2014	32
25115304	1956	Sorich MJ	Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.	Annals of oncology 	2015	68
25122430	1956	Douillard JY	Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.	Journal of thoracic oncology 	2014	63
25137181	1956	Marchetti A	Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.	PloS one	2014	33
25150284	1956	Labussière M	Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.	Neurology	2014	29
25164765	1956	Brannon AR	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.	Genome biology	2014	54
25175099	1956	Seto T	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.	The Lancet. Oncology	2014	67
25193862	1956	Wilson C	Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.	Oncotarget	2014	29
25222496	1956	Zhang Y	Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.	PloS one	2014	27
25247337	1956	Hoffknecht P	Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.	Journal of thoracic oncology 	2015	25
25248381	1956	Laurent-Puig P	Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy.	Clinical cancer research 	2015	30
25271963	1956	Finlay MR	Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.	Journal of medicinal chemistry	2014	27
25311215	1956	Leighl NB	Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.	Journal of clinical oncology 	2014	42
25339418	1956	Qiu M	Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.	Cancer epidemiology, biomarkers and prevention 	2015	30
25349291	1956	Iyengar P	Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.	Journal of clinical oncology 	2014	23
25394791	1956	Crystal AS	Patient-derived models of acquired resistance can identify effective drug combinations for cancer.	Science	2014	120
25405807	1956	Wang Z	Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.	PloS one	2014	31
25444907	1956	Hao C	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.	Cancer letters	2015	18
25468223	1956	Cohen AL	Glioma biology and molecular markers.	Cancer treatment and research	2015	26
25567908	1956	Drilon A	Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.	Clinical cancer research 	2015	30
25589191	1956	Yang JC	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.	The Lancet. Oncology	2015	173
25593032	1956	Linnekamp JF	Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes.	Cancer research	2015	21
25593300	1956	Cani AK	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	Molecular cancer research 	2015	19
25605843	1956	Van Cutsem E	Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.	Journal of clinical oncology 	2015	74
25623215	1956	Arena S	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.	Clinical cancer research 	2015	24
25628445	1956	Morelli MP	Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.	Annals of oncology 	2015	22
25629635	1956	Wu C	High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.	Journal of thoracic oncology 	2015	16
25639985	1956	Mao C	Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases.	Scientific reports	2015	19
25649416	1956	Stahl P	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.	BMC gastroenterology	2015	17
25667274	1956	Lopez-Chavez A	Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.	Journal of clinical oncology 	2015	33
25673558	1956	Pietrantonio F	Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.	European journal of cancer	2015	37
25673644	1956	Ahronian LG	Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.	Cancer discovery	2015	46
25689095	1956	Kumarakulasinghe NB	Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).	Respirology	2015	16
25738220	1956	Sholl LM	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.	Journal of thoracic oncology 	2015	37
25758528	1956	Niederst MJ	RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.	Nature communications	2015	45
25769900	1956	Zhu G	Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell-Free DNA from Patients with Advanced Non-Small Cell Lung Cancer.	The Journal of molecular diagnostics 	2015	22
25807554	1956	Tang MC	Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.	PloS one	2015	15
25829397	1956	Mok T	Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.	Clinical cancer research 	2015	43
25870145	1956	Eberlein CA	Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.	Cancer research	2015	31
25882755	1956	Watanabe M	Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR.	Clinical cancer research 	2015	37
25895031	1956	Tang Y	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.	Oncotarget	2015	32
25897154	1956	Lee CK	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.	Journal of clinical oncology 	2015	32
25923549	1956	Jänne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	230
25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
25934077	1956	Piotrowska Z	Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.	Cancer discovery	2015	57
25943888	1956	Aldape K	Glioblastoma: pathology, molecular mechanisms and markers.	Acta neuropathologica	2015	25
25956936	1956	Rizzo S	CT Radiogenomic Characterization of EGFR, K-RAS, and ALK Mutations in Non-Small Cell Lung Cancer.	European radiology	2016	12
25964297	1956	Niederst MJ	The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.	Clinical cancer research 	2015	42
25989278	1956	Rowland A	Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.	British journal of cancer	2015	21
26014294	1956	Zhou C	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2015	26
26024796	1956	Cooper WA	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.	Lung cancer	2015	30
26030179	1956	Siravegna G	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.	Nature medicine	2015	58
26036643	1956	Tricker EM	Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.	Cancer discovery	2015	28
26051236	1956	Yang JC	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.	The Lancet. Oncology	2015	40
26105600	1956	Wu YL	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.	Annals of oncology 	2015	30
26124204	1956	Della Corte CM	SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.	Clinical cancer research 	2015	18
26141208	1956	Zhou C	Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).	Annals of oncology 	2015	39
26159065	1956	Soria JC	Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.	The Lancet. Oncology	2015	50
26206882	1956	Uchida J	Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA.	Clinical chemistry	2015	25
26227959	1956	Sun W	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer.	Journal of hematology and oncology	2015	25
26243863	1956	Kavuri SM	HER2 activating mutations are targets for colorectal cancer treatment.	Cancer discovery	2015	18
26269204	1956	Planchard D	EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.	Annals of oncology 	2015	26
26295376	1956	Marchetti A	Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.	Journal of thoracic oncology 	2015	26
26308162	1956	Russo A	A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.	Oncotarget	2015	30
26318427	1956	Bronte G	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?	Oncotarget	2015	16
26324367	1956	Masters GA	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.	Journal of clinical oncology 	2015	48
26354927	1956	Dubbink HJ	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.	Neuro-oncology	2016	15
26358176	1956	Dietel M	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.	Cancer gene therapy	2015	25
26392535	1956	Kamburov A	Comprehensive assessment of cancer missense mutation clustering in protein structures.	Proceedings of the National Academy of Sciences of the United States of America	2015	26
26410082	1956	Brastianos PK	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.	Cancer discovery	2015	52
26416997	1956	Cai W	Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.	Journal of clinical oncology 	2015	21
26434585	1956	Schneider MR	The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.	Oncogene	2016	12
26438111	1956	Allegra CJ	Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015.	Journal of clinical oncology 	2016	33
26446944	1956	Sundaresan TK	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.	Clinical cancer research 	2016	45
26460303	1956	Kopetz S	Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.	Journal of clinical oncology 	2015	42
26477306	1956	Schabath MB	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.	Oncogene	2016	11
26494259	1956	Thress KS	EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.	Lung cancer	2015	39
26525104	1956	Best MG	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.	Cancer cell	2015	34
26537995	1956	Minguet J	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.	International journal of cancer	2016	19
26577492	1956	Sueoka-Aragane N	Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.	Cancer science	2016	13
26582655	1956	Xu S	Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.	Cancer letters	2016	12
26625312	1956	Pécuchet N	Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.	Oncotarget	2017	5
26644315	1956	Russo M	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.	Cancer discovery	2016	23
26690310	1956	Richman SD	HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.	The Journal of pathology	2016	11
26724471	1956	Lin JJ	Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.	Journal of thoracic oncology 	2016	12
26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
26729443	1956	Awad MM	MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.	Journal of clinical oncology 	2016	33
26755650	1956	Lee JY	Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).	Oncotarget	2016	17
26777916	1956	Barlesi F	Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).	Lancet	2016	43
26789630	1956	Yoshida T	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PloS one	2016	13
26799287	1956	Del Re M	Contribution of KRAS mutations and c.2369C &amp;gt; T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.	Oncotarget	2017	9
26823294	1956	Schuler M	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.	Journal of thoracic oncology 	2016	12
26828195	1956	Hata AN	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.	Nature medicine	2016	57
26843189	1956	Arena S	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.	Science translational medicine	2016	11
26844548	1956	Hedner C	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.	PloS one	2016	11
26867973	1956	Zheng D	Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.	Scientific reports	2016	30
26898616	1956	Tan CS	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.	Lung cancer	2016	17
26942675	1956	Li X	Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis.	Molecular cell	2016	15
27060149	1956	Lai Z	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research.	Nucleic acids research	2016	12
27071706	1956	Wang S	Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.	Journal of hematology and oncology	2016	29
27083334	1956	Park K	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.	The Lancet. Oncology	2016	46
27354477	1956	Oxnard GR	Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.	Journal of clinical oncology 	2016	32
27688480	1956	Yip SS	Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.	Journal of nuclear medicine 	2017	7
27922044	1956	Punt CJ	From tumour heterogeneity to advances in precision treatment of colorectal cancer.	Nature reviews. Clinical oncology	2017	5
27959700	1956	Mok TS	Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.	The New England journal of medicine	2017	44
20877296	2064	Carey L	Triple-negative breast cancer: disease entity or title of convenience?	Nature reviews. Clinical oncology	2010	180
22325357	2064	De Grève J	Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.	Lung cancer	2012	47
22761469	2064	Arcila ME	Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.	Clinical cancer research 	2012	53
22956644	2064	Takezawa K	HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.	Cancer discovery	2012	136
23220880	2064	Bose R	Activating HER2 mutations in HER2 gene amplification negative breast cancer.	Cancer discovery	2013	137
24829859	2064	Yadav BS	Systemic treatment strategies for triple-negative breast cancer.	World journal of clinical oncology	2014	24
18381441	2065	Kunii K	FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.	Cancer research	2008	65
24097870	2146	Behrens C	EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.	Clinical cancer research 	2013	33
23340843	2317	Reimand J	Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers.	Molecular systems biology	2013	71
20534479	3082	Grugan KD	Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion.	Proceedings of the National Academy of Sciences of the United States of America	2010	42
19636000	3417	Sanson M	Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.	Journal of clinical oncology 	2009	178
19755387	3417	Nobusawa S	IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.	Clinical cancer research 	2009	117
20160062	3417	van den Bent MJ	IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.	Clinical cancer research 	2010	88
22415316	3417	Gorovets D	IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.	Clinical cancer research 	2012	40
20351332	3480	Dziadziuszko R	Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.	Journal of clinical oncology 	2010	45
24489728	3480	Murakami A	Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.	PloS one	2014	25
22327624	3799	Kohno T	KIF5B-RET fusions in lung adenocarcinoma.	Nature medicine	2012	171
16618717	3845	Lièvre A	KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.	Cancer research	2006	491
17184525	3845	Krypuy M	High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer.	BMC cancer	2006	78
18316791	3845	Amado RG	Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.	Journal of clinical oncology 	2008	729
18669866	3845	Perrone F	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.	Annals of oncology 	2009	112
18804418	3845	Linardou H	Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.	The Lancet. Oncology	2008	184
19001320	3845	Di Nicolantonio F	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.	Journal of clinical oncology 	2008	416
19196673	3845	Tol J	Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.	The New England journal of medicine	2009	288
19349489	3845	Riely GJ	KRAS mutations in non-small cell lung cancer.	Proceedings of the American Thoracic Society	2009	142
19398573	3845	Loupakis F	PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.	Journal of clinical oncology 	2009	123
19603018	3845	Loupakis F	KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.	British journal of cancer	2009	136
19738126	3845	Jacobs B	Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.	Journal of clinical oncology 	2009	84
19884549	3845	Richman SD	KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.	Journal of clinical oncology 	2009	146
19934290	3845	Ogino S	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.	Clinical cancer research 	2009	62
20022659	3845	Mao C	KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies.	Lung cancer	2010	74
20413299	3845	Tol J	Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.	European journal of cancer	2010	61
20570890	3845	Janakiraman M	Genomic and biological characterization of exon 4 KRAS mutations in human cancer.	Cancer research	2010	92
20619739	3845	De Roock W	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.	The Lancet. Oncology	2010	475
21305640	3845	Vaughn CP	Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.	Genes, chromosomes and cancer	2011	59
21632860	3845	Molinari F	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.	Clinical cancer research 	2011	56
22798500	3845	Tian S	A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.	Gut	2013	26
23122493	3845	Karachaliou N	KRAS mutations in lung cancer.	Clinical lung cancer	2013	31
23182985	3845	Peeters M	Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.	Journal of clinical oncology 	2013	63
23293113	3845	Tougeron D	Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.	Annals of oncology 	2013	29
23374602	3845	Pentheroudakis G	Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.	BMC cancer	2013	33
23725851	3845	Seymour MT	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.	The Lancet. Oncology	2013	65
24024839	3845	Douillard JY	Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.	The New England journal of medicine	2013	383
21175304	4792	Bredel M	NFKBIA deletion in glioblastomas.	The New England journal of medicine	2011	77
23515407	4893	Ohashi K	Characteristics of lung cancers harboring NRAS mutations.	Clinical cancer research 	2013	30
18757405	5290	Yamamoto H	PIK3CA mutations and copy number gains in human lung cancers.	Cancer research	2008	140
19223544	5290	Sartore-Bianchi A	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.	Cancer research	2009	197
22039088	5290	Mao C	PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.	Annals of oncology 	2012	51
22285706	5290	Sood A	PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.	Clinical colorectal cancer	2012	33
24533074	5290	Wang L	PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.	PloS one	2014	25
25099740	5290	Wang Z	mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.	Journal of the National Cancer Institute	2014	22
17940504	5728	Frattini M	PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.	British journal of cancer	2007	135
22661537	6098	Rimkunas VM	Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.	Clinical cancer research 	2012	53
11960372	6774	Niu G	Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.	Oncogene	2002	292
23955565	7015	Nonoguchi N	TERT promoter mutations in primary and secondary glioblastomas.	Acta neuropathologica	2013	41
25314060	7015	Labussière M	TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.	British journal of cancer	2014	29
17927446	10018	Gong Y	Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.	PLoS medicine	2007	114
17973572	10018	Costa DB	BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.	PLoS medicine	2007	162
17973573	10018	Cragg MS	Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.	PLoS medicine	2007	112
23382048	10018	Nakagawa T	EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.	Cancer research	2013	36
23559152	10018	Lee JK	Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.	Annals of oncology 	2013	29
24493829	10018	Costa C	The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.	Clinical cancer research 	2014	48
26579470	10018	Huang L	Mechanisms of resistance to EGFR tyrosine kinase inhibitors.	Acta pharmaceutica Sinica. B	2015	30
23782814	10801	Wu YL	Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.	The Lancet. Oncology	2013	70
22195963	11186	Matallanas D	Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.	Molecular cell	2011	43
16943533	81552	Chung CH	Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.	Journal of clinical oncology 	2006	134
17671655	140803	Groenestege WM	Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia.	The Journal of clinical investigation	2007	58
